RxDoctor Payments Data

Nazanin Azadi, MD

Internal Medicine · Los Angeles, CANPI 1558595082

Payments from drug & device makers

$1,567in general payments, 2019–2025

Across 72 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$781
  • Astellas Pharma US Inc$198
  • Boston Scientific$171
  • Abbott$118
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$64
  • Cook Medical LLC$61
  • plus $175 from 5 others

What the payments were for

  • Food & beverage$1,38789%
  • Education$18011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,567 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$256,242
Medicare patients
1,188
Services billed
3,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban285$356,198
XareltoRivaroxaban71$85,717
EntrestoSacubitril/Valsartan28$36,525
BrilintaTicagrelor18$13,145
LivaloPitavastatin Calcium13$8,131
Nebivolol Hcl26$3,147
Atorvastatin Calcium341$2,707
Metoprolol Succinate143$2,449
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$2,305
Losartan Potassium182$2,001
Amlodipine Besylate210$1,569
Valsartan47$1,283
Metoprolol Tartrate200$1,183
Dilt-XrDiltiazem Hcl22$1,132
Rosuvastatin Calcium88$931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$356,198285 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →